Esophageal Diseases
Welcome,         Profile    Billing    Logout  
 128 Companies   121 Products   121 Products   104 Mechanisms of Action   7 Trials   1812 News 


«12345678910111213...3637»
  • ||||||||||  Trial primary completion date:  Sleep Position May Reduce Acid Reflux Symptoms at Night (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=20, Enrolling by invitation, 
    Trial primary completion date: Sep 2016 --> Sep 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Mucosal Impedance in Pediatric Population (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=127, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=198 --> 127 | Trial primary completion date: Dec 2016 --> Sep 2016
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date, Reflex:  Cough Reflex Sensitivity and Bronchial Hyper-responsiveness (clinicaltrials.gov) -  Feb 17, 2017   
    P=N/A,  N=24, Completed, 
    Recruiting --> Completed | N=198 --> 127 | Trial primary completion date: Dec 2016 --> Sep 2016 Recruiting --> Completed | N=36 --> 24 | Trial primary completion date: Dec 2016 --> Feb 2016
  • ||||||||||  prednisone / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Reduction in Symptomatic Esophageal Stricture Formation (clinicaltrials.gov) -  Feb 14, 2017   
    P4,  N=3, Completed, 
    Recruiting --> Completed | N=36 --> 24 | Trial primary completion date: Dec 2016 --> Feb 2016 Recruiting --> Completed | N=126 --> 3 | Trial primary completion date: Mar 2017 --> Feb 2015
  • ||||||||||  Enrollment open:  The Turkish Feeding/Swallowing Impact Survey (clinicaltrials.gov) -  Feb 10, 2017   
    P=N/A,  N=150, Recruiting, 
    Phase classification: P4 --> P=N/A Not yet recruiting --> Recruiting
  • ||||||||||  Trial primary completion date, Metastases:  ATTACK-OG: NY-ESO-1 T Cells in OG Cancer (clinicaltrials.gov) -  Feb 8, 2017   
    P2,  N=28, Active, not recruiting, 
    Recruiting --> Completed | N=20 --> 12 Trial primary completion date: Dec 2016 --> Dec 2018
  • ||||||||||  Phase classification:  RELIEF Europe Study (clinicaltrials.gov) -  Feb 6, 2017   
    P=N/A,  N=7, Terminated, 
    Trial primary completion date: Jun 2017 --> Feb 2018 Phase classification: P4 --> P=N/A
  • ||||||||||  azacitidine / Generic mfg.
    Enrollment closed, Enrollment change, Trial primary completion date:  VEOX: Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer (clinicaltrials.gov) -  Jan 26, 2017   
    P1,  N=12, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2019 --> Jun 2018 Recruiting --> Active, not recruiting | N=16 --> 12 | Trial primary completion date: Jun 2012 --> Aug 2014
  • ||||||||||  oxaliplatin / Generic mfg., capecitabine / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    Enrollment closed, Trial primary completion date, Metastases:  The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) (clinicaltrials.gov) -  Jan 26, 2017   
    P1/2,  N=154, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=16 --> 12 | Trial primary completion date: Jun 2012 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Sep 2017
  • ||||||||||  fluorouracil topical / Generic mfg., cisplatin / Generic mfg.
    Trial primary completion date, HEOR, Metastases:  Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia. (clinicaltrials.gov) -  Jan 24, 2017   
    P3,  N=220, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Sep 2017 Trial primary completion date: Jul 2012 --> Mar 2012
  • ||||||||||  Trial primary completion date:  Positron Emission Tomography in Determining Stage of Esophageal Cancer (clinicaltrials.gov) -  Jan 24, 2017   
    P=N/A,  N=235, Completed, 
    Trial primary completion date: Jul 2012 --> Mar 2012 Trial primary completion date: Jan 2009 --> Jul 2005
  • ||||||||||  Trial primary completion date, FDG PET:  4D FDG PET in Esophageal Cancer (clinicaltrials.gov) -  Jan 23, 2017   
    P=N/A,  N=30, Recruiting, 
    Trial primary completion date: Jan 2009 --> Jul 2005 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Trial completion, Trial primary completion date:  Transparent Cap-assisted Endoscopic Sclerotherapy (clinicaltrials.gov) -  Jan 17, 2017   
    P=N/A,  N=120, Completed, 
    Recruiting --> Completed | N=18 --> 80 Not yet recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
    Enrollment change:  Rifaximin in Patients With Gastroesophageal Variceal Bleeding (clinicaltrials.gov) -  Jan 11, 2017   
    P=N/A,  N=50, Recruiting, 
    Trial primary completion date: Dec 2016 --> Jun 2017 N=100 --> 50
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date, Surgery:  Prospective Pediatric Vesicoureteral Reflux Surgery Database (clinicaltrials.gov) -  Jan 5, 2017   
    P=N/A,  N=134, Completed, 
    N=100 --> 50 Recruiting --> Completed | N=200 --> 134 | Trial primary completion date: Jul 2012 --> Nov 2016
  • ||||||||||  Preclinical, Trial initiation date, Trial primary completion date:  In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter (clinicaltrials.gov) -  Dec 29, 2016   
    P=N/A,  N=100, Recruiting, 
    Not yet recruiting --> Recruiting | N=20 --> 120 | Initiation date: Mar 2017 --> Jun 2014 Initiation date: Feb 2005 --> Feb 2008 | Trial primary completion date: Dec 2015 --> Jun 2017
  • ||||||||||  Trial primary completion date:  NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer (clinicaltrials.gov) -  Dec 21, 2016   
    P0,  N=10, Active, not recruiting, 
    Initiation date: Jul 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Dec 2017